Provided by Tiger Trade Technology Pte. Ltd.

Pulse Biosciences

20.57
-0.9300-4.33%
Post-market: 20.570.00000.00%16:34 EDT
Volume:154.08K
Turnover:3.18M
Market Cap:1.39B
PE:-19.05
High:21.62
Open:21.60
Low:20.23
Close:21.50
52wk High:26.30
52wk Low:12.56
Shares:67.77M
Float Shares:17.44M
Volume Ratio:0.66
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0799
EPS(LYR):-1.0800
ROE:-74.45%
ROA:-42.37%
PB:17.28
PE(LYR):-19.05

Loading ...

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live
·
Feb 07

Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Study Results

TIPRANKS
·
Feb 06

Pulse Biosciences präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern

Reuters
·
Feb 06

Pulse Biosciences Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht

Reuters
·
Feb 05

Pulse Biosciences Reports Positive 12-Month Data for Nanosecond PFA Catheter in Atrial Fibrillation Study

Reuters
·
Feb 03

Mizuho Securities Initiates Coverage on Pulse Biosciences With Outperform Rating

MT Newswires Live
·
Jan 30

Pulse Biosciences Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $25

THOMSON REUTERS
·
Jan 30

Pulse Biosciences initiated with an Outperform at Mizuho

TIPRANKS
·
Jan 30

New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE)

Simply Wall St.
·
Jan 13

Assessing Pulse Biosciences (PLSE) Valuation After Upcoming nPulse Cardiac Study Data Presentation

Simply Wall St.
·
Jan 09

Pulse Biosciences Appoints Maria Sainz to Board of Directors

Reuters
·
Jan 09

Pulse Biosciences Unveils Late-Breaking Data from nPulse Cardiac Catheter Study at AF Symposium

Reuters
·
Jan 06

Pulse Biosciences to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 30, 2025

Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial

Simply Wall St.
·
Dec 23, 2025

BRIEF-Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Dec 20, 2025

Pulse Biosciences Grants Inducement Stock Options to New Employees

Reuters
·
Dec 20, 2025

Pulse Biosciences Wins FDA IDE Approval for nPulse Cardiac Catheter Study

Reuters
·
Dec 18, 2025

Pulse Biosciences Announces FDA Ide Approval to Initiate Its Npulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

THOMSON REUTERS
·
Dec 18, 2025

Pulse Biosciences Partners with MD Anderson to Study Thyroid Cancer Treatment

Reuters
·
Dec 09, 2025

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors With Npulse™ Technology

THOMSON REUTERS
·
Dec 09, 2025